Indices
FIDSON
| Price | Today's Change | Avg daily Volume | 1 Year Change | 52 Week Range |
|---|---|---|---|---|
| 43.90 | 0.00 (0.00%) | 1.29M | 29.15 (197.63%) | 12.40 - 47.00 |
Data in real-time, as of 8/5/2025 3:32:37 PM
3 Months Trend
Profile
Fidson Healthcare Plc engages in the manufacture and distribution of pharmaceutical products in Nigeria. The company offers pharmaceutical products in various therapeutic areas, such as anti-infective, anti-arthritis, endocrinology, gastro-intestine, anti-retroviral, anti-malaria, cardiovascular, anti-depressant, pain relievers, haematinics, cough expectorants, and consumer goods. Its principal products include Biosulin-N, which is an anti-diabetic insulin; Gascol for heartburn, indigestion, dyspepsia, flatulence, and other acid-related disorders; Asomex 2.5 for acute uncomplicated UTI, complicated UTI, enteric fever, bone and joint infections, and adnexitis and prostatitis2; and Cutenox for the prevention of thrombosis in hospitalized medical and surgical patients. The company also offers Flutex for patients with depressive disorder, obsessive compulsive disorders, and bulima nervosa; Ciprotab 500, a second generation fluoroquinolone antibiotic for the treatment of various infections; ZETGEL to relieve pain in osteoarthrtis; and Astyfer Blood Builder for use in pregnancy, lactation, anaemia, haemorrhoids, anal fissures, chronic gastric ulcers, and iron deficiency; and Tuxil-C cough expectorant. In addition, it provides Formula 103, a razor less hair removal for men and women; baby diapers under Cuddles name; and tissue products under Fluffy brand. The company was incorporated in 1995 and is headquartered in Lagos, Nigeria. Website: www.fidson.com Founded in: 1995
Quotes
| LClose | 43.90 | Price | 43.90 |
|---|---|---|---|
| Change | 0.00 (0.00%) | Low | 43.90 |
| High | 43.90 | EPS | 0.64 |
| 52WkHigh | 47.00 | 52WkLow | 12.40 |
| 50d Mov Avg | 40.44 | 200d Mov Avg | 23.60 |
| AvgDlyVol | 1.29M | 3MthChg | 21.05 (92.12%) |
| 6MthChg | 26.50 (152.30%) | 12MthChg | 29.15 (197.63%) |
| Beta | 0.2481931 | Risk Factor | 0.006294806 |
| PE | 22.54 | Shares Outs. | 2.29B |
| Div. Yield | 4.14 | Market Cap | 100.75B |
| Volume | 1.94M | # Of Trades | 510 |
| Trades Value | 77.66M | ||
| Sector | Pharmaceuticals | ||
Income statement
Statement of Comprehensive Income as at
31-Mar-2018
| Name | Amount |
|---|---|
| Revenue | 16,229,903.00 |
| Profit before taxation | 160,867.00 |
| Taxation | 258,314.00 |
| Profit after tax | -97,447.00 |
| Transfer to revenue reserve | -322,447.00 |
| Profit attributable to: | |
| Owners of the company | -97,447.00 |
| Non-controlling interest | |
| Earnings per 50k share (k) | -6.00 |
| Net assets per 50k share (k) | 477.00 |
Board of directors
| Name | Title |
|---|---|
| Felix Ohiwerei | Chairman of the Board |
| Fidelis Ayebae | Chief Executive Officer/ Managing Director, Director |
| Olatunde Olanipekun | Finance Director, Executive Director |
| Abiola Adebayo | Operations Director, Executive Director |
| Olugbenga Olayeye | Executive Director, Sales and Marketing Director |
| Abayomi Adebanyo | Company Secretary |
| Olufunmilola Ayebae | Non-Executive Director |
| Emmanuel Imoagene | Non-Executive Director |
| Aishatu Sadauki | Non-Executive Director |
Currency
| Currency | Rate(₦) |
|---|---|
| USD USD/NGN | 1,521.44 |
| GBP GBP/NGN | 2,020.26 |
| EUR EUR/NGN | 1,762.43 |
| JPY JPY/NGN | 10.33 |
| CAD CAD/NGN | 1,104.12 |
| CNY CNY/NGN | 210.97 |
| AUD AUD/NGN | 983.79 |
| XOF XOF/NGN | 2.69 |
| XAF XAF/NGN | 2.69 |
| GHS GHS/NGN | 146.70 |
| AED AED/NGN | 414.23 |
| ZAR ZAR/NGN | 84.05 |
| JPY JPY/NGN | 10.33 |
| KES KES/NGN | 11.89 |
| EGP EGP/NGN | 31.46 |
| INR INR/NGN | 17.44 |
| AUD AUD/NGN | 983.79 |
| CHF CHF/NGN | 1,891.90 |
| DZD DZD/NGN | 11.68 |
| MAD MAD/NGN | 168.48 |
| AOA AOA/NGN | 1.66 |
| TZS TZS/NGN | 0.61 |
| BWP BWP/NGN | 112.63 |
| ETB ETB/NGN | 11.16 |
| NAD NAD/NGN | 84.30 |
| SDG SDG/NGN | 2.53 |
| MZN MZN/NGN | 23.79 |
| SLL SLL/NGN | 0.07 |
| MWK MWK/NGN | 0.89 |
| GMD GMD/NGN | 20.99 |
| BIF BIF/NGN | 0.52 |
| GNF GNF/NGN | 0.18 |
| LRD LRD/NGN | 7.62 |
| SZL SZL/NGN | 84.31 |
| CVE CVE/NGN | 15.96 |
| RWF RWF/NGN | 1.07 |
| DJF DJF/NGN | 8.65 |
| ERN ERN/NGN | 101.43 |
| ZMW ZMW/NGN | 67.55 |
